La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

China National Medicines Crescita futura

Future criteri di controllo 1/6

China National Medicines prevede che gli utili e i ricavi cresceranno rispettivamente di 10.2% e 9.2% all'anno. Si prevede che l'EPS crescerà di 10.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.9% in 3 anni.

Informazioni chiave

11.4%

Tasso di crescita degli utili

11.3%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	21.5%
Tasso di crescita dei ricavi	10.1%
Rendimento futuro del capitale proprio	13.7%
Copertura analitica	Low
Ultimo aggiornamento	22 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28

Previsioni di crescita degli utili e dei ricavi

SHSE:600511 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	64,974	2,897	N/A	2,820	4
12/31/2025	59,149	2,616	N/A	2,324	5
12/31/2024	53,966	2,382	N/A	1,949	4
6/30/2024	50,312	2,162	1,688	1,827	N/A
3/31/2024	50,592	2,191	2,008	2,151	N/A
12/31/2023	49,696	2,146	2,582	2,727	N/A
9/30/2023	47,486	1,995	2,466	2,602	N/A
6/30/2023	47,632	2,086	2,040	2,194	N/A
3/31/2023	45,665	2,005	2,429	2,560	N/A
12/31/2022	45,499	1,964	2,265	2,395	N/A
9/30/2022	46,719	1,884	1,336	1,460	N/A
6/30/2022	46,399	1,850	1,081	1,185	N/A
3/31/2022	47,185	1,830	1,746	1,851	N/A
12/31/2021	46,469	1,754	1,862	1,957	N/A
9/30/2021	45,559	1,680	1,085	1,170	N/A
6/30/2021	44,923	1,529	1,129	1,197	N/A
3/31/2021	42,512	1,449	1,187	1,247	N/A
12/31/2020	40,379	1,383	1,233	1,302	N/A
9/30/2020	41,046	1,537	1,058	1,125	N/A
6/30/2020	41,153	1,469	1,922	1,997	N/A
3/31/2020	42,805	1,549	1,399	1,477	N/A
12/31/2019	44,644	1,604	1,690	1,776	N/A
9/30/2019	42,673	1,525	1,037	1,139	N/A
6/30/2019	40,991	1,523	1,024	1,159	N/A
3/31/2019	39,659	1,436	-33	103	N/A
12/31/2018	38,740	1,404	849	982	N/A
9/30/2018	37,994	1,256	2,457	2,576	N/A
6/30/2018	37,452	1,224	1,977	2,058	N/A
3/31/2018	36,653	1,163	N/A	1,424	N/A
12/31/2017	36,285	1,141	N/A	1,074	N/A
9/30/2017	36,072	1,060	N/A	63	N/A
6/30/2017	35,540	1,044	N/A	-85	N/A
3/31/2017	40,103	1,101	N/A	488	N/A
12/31/2016	34,611	990	N/A	1,043	N/A
9/30/2016	28,613	887	N/A	461	N/A
6/30/2016	22,813	752	N/A	716	N/A
3/31/2016	12,408	527	N/A	445	N/A
12/31/2015	12,078	513	N/A	440	N/A
9/30/2015	12,065	499	N/A	307	N/A
6/30/2015	11,894	499	N/A	424	N/A
3/31/2015	11,773	490	N/A	394	N/A
12/31/2014	11,538	483	N/A	219	N/A
9/30/2014	11,177	465	N/A	338	N/A
6/30/2014	10,824	457	N/A	240	N/A
3/31/2014	10,408	431	N/A	204	N/A
12/31/2013	10,081	412	N/A	186	N/A
9/30/2013	9,667	384	N/A	221	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600511 ( 10.2% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 600511 ( 10.2% all'anno) cresceranno più lentamente rispetto al mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600511 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 600511 ( 9.2% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600511 ( 9.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600511 sarà basso tra 3 anni ( 13.9 %).

China National Medicines Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 14% to CN¥46.58

Price target decreased to CN¥39.20

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Now 20% undervalued

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Dividend increased to CN¥0.85

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

China National Medicines (SHSE:600511) Could Easily Take On More Debt

China National Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 21, 2024

Third quarter 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.76 in 3Q 2022)

China National Medicines Corporation Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2022)

Price target increased by 14% to CN¥46.58

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.71 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.65 (vs CN¥0.62 in 2Q 2021)

China National Medicines Corporation Ltd.(XSSC:600511) dropped from S&P Global BMI Index

China National Medicines Corporation Ltd.(XSSC:600511) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥39.20

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.51 in 2Q 2020)

Upcoming dividend of CN¥0.55 per share

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.83 (vs CN¥2.11 in FY 2019)

New 90-day low: CN¥36.33

New 90-day low: CN¥41.32

China National Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

New 90-day high: CN¥50.10

Third quarter earnings released

China National Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Earnings released

New 90-day high - CN¥52.00

China National Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 19, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita